Exogenous surfactants in a piglet model of acute respiratory distress syndrome.
Evidence for surfactant dysfunction in acute respiratory distress syndrome (ARDS) suggests a role for exogenous surfactant which contains apoprotein for resistance to protein inhibition. We compared the effects of KL-4-Surfactant, an artificial preparation containing a synthetic 21 amino acid peptide with SP-B-like activity, with Exosurf, an artificial protein-free surfactant, and Survanta, a bovine protein-containing surfactant, in a saline lung lavage model of ARDS in neonatal piglets. Two sequential series of lung lavages were performed to lower PaO2 < 100 mm Hg, each followed by administration of surfactant or air and a 90-min observation period. Progressive lung injury was demonstrated by deterioration in pulmonary function, increasing bronchoalveolar lavage protein, and changes in histopathology. All surfactants improved oxygenation, although oxygenation was generally better with Survanta and KL-4-Surfactant. Further, Survanta and KL-4-Surfactant groups showed improvement in ventilation, with decreases in PaCO2 and increases in FRC. Only KL-4-Surfactant demonstrated greater pressure-volume characteristics and lower bronchoalveolar protein than those of Controls. We conclude that the physiologic effects of KL-4-Surfactant are more like Survanta in this model. We speculate that KL-4-Surfactant may improve pulmonary function, reduce alveolar protein leak, and thus be efficacious in the treatment of ARDS.
Sood
S L
SL
Department of Pediatrics, Kapiolani Medical Center for Women and Children, John A. Burns School of Medicine, Honolulu, Hawaii 96826, USA.
Balaraman
V
V
Finn
K C
KC
Britton
B
B
Uyehara
C F
CF
Easa
D
D
D000818:Animals; D000831:Animals, Newborn; D001688:Biological Products; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D004338:Drug Combinations; D005233:Fatty Alcohols / Q000627:therapeutic use; D005652:Functional Residual Capacity; D036341:Intercellular Signaling Peptides and Proteins; D008168:Lung / Q000473:pathology; D010455:Peptides / Q000627:therapeutic use; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D015656:Respiratory Mechanics; D013552:Swine
D001688:Biological Products; D004338:Drug Combinations; D005233:Fatty Alcohols; D036341:Intercellular Signaling Peptides and Proteins; C097558:KL4 surfactant; D010455:Peptides; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D011092:Polyethylene Glycols; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination; C072197:beractant